Literature DB >> 16436139

Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils.

V Kvedariene1, S Kamey, Y Ryckwaert, M Rongier, J Bousquet, P Demoly, B Arnoux.   

Abstract

BACKGROUND: Immunoglobulin E (IgE)-mediated hypersensitivity reactions to neuromuscular blocking agents (NMBA) are common and life threatening. Basophil activation based upon the expression of CD63 in the presence of specific allergens was found to be of importance for the diagnosis of IgE-mediated hypersensibility.
METHODS: The Basotest was evaluated for the diagnosis of NMBA in 47 patients with proven NMBA anaphylaxis, 40 atopic subjects nonallergic to NMBA and five healthy volunteers. Diagnosis of NMBA was made according to international standards on clinical history, skin tests and provocation tests when needed.
RESULTS: In the NMBA allergic patients, sensitivity of Basotest was 36.1%, but it increased to 85.7% for reactions which occurred within the last 3 years. The specificity was 93.3%.
CONCLUSION: Basotest may be useful for the diagnosis of NMBA allergy in patients with a suspicion of recent IgE-mediated hypersensitivity reaction to NMBA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436139     DOI: 10.1111/j.1398-9995.2006.00978.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  19 in total

1.  [Anesthetic incompatibility--rare, but dangerous].

Authors:  G Wurpts; J M Baron
Journal:  Hautarzt       Date:  2007-01       Impact factor: 0.751

Review 2.  Pros and Cons of Clinical Basophil Testing (BAT).

Authors:  Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

Review 3.  Update on Quinolone Allergy.

Authors:  Inmaculada Doña; Esther Moreno; Natalia Pérez-Sánchez; Inmaculada Andreu; Dolores Hernández Fernandez de Rojas; María José Torres
Journal:  Curr Allergy Asthma Rep       Date:  2017-08       Impact factor: 4.806

Review 4.  Response to Ebo et al., Letter to the Editor Regarding Update on Quinolone Allergy.

Authors:  Inmaculada Doña; Esther Moreno; Natalia Pérez-Sánchez; Inmaculada Andreu; Dolores Hernández Fernandez de Rojas; María José Torres
Journal:  Curr Allergy Asthma Rep       Date:  2017-10-04       Impact factor: 4.806

Review 5.  BAT in the Diagnosis of Drug Allergy: a Novel Tool in Clinical Daily Practice?

Authors:  Lucila Campos; Violeta Régnier Galvão; Jorge Kalil; Mariana Castells; Pedro Giavina-Bianchi
Journal:  Curr Allergy Asthma Rep       Date:  2019-03-11       Impact factor: 4.806

Review 6.  Practical guidelines for the response to perioperative anaphylaxis.

Authors:  Tomonori Takazawa; Ken Yamaura; Tetsuya Hara; Tomoko Yorozu; Hiromasa Mitsuhata; Hiroshi Morimatsu
Journal:  J Anesth       Date:  2021-10-14       Impact factor: 2.078

7.  Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease.

Authors:  G E Celik; J T Schroeder; R G Hamilton; S S Saini; N F Adkinson
Journal:  Clin Exp Allergy       Date:  2009-05-22       Impact factor: 5.018

8.  Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites.

Authors:  Andrea Harrer; Roland Lang; Robert Grims; Michaela Braitsch; Thomas Hawranek; Werner Aberer; Lothar Vogel; Walther Schmid; Fatima Ferreira; Martin Himly
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

Review 9.  Recent applications of basophil activation tests in the diagnosis of drug hypersensitivity.

Authors:  Woo-Jung Song; Yoon-Seok Chang
Journal:  Asia Pac Allergy       Date:  2013-10-31

10.  Threshold for basophil activation test positivity in neuromuscular blocking agents hypersensitivity reactions.

Authors:  Natalia Hagau; Nadia Gherman-Ionica; Manuela Sfichi; Cristina Petrisor
Journal:  Allergy Asthma Clin Immunol       Date:  2013-10-23       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.